AT409863B - Hoch effiziente expression eines polypeptids, das eine modifizierte pres1-region des grossen hepatitis b-virus-antigens enthält - Google Patents

Hoch effiziente expression eines polypeptids, das eine modifizierte pres1-region des grossen hepatitis b-virus-antigens enthält Download PDF

Info

Publication number: AT409863B
Authority: AT; Austria
Prior art keywords: antigen; pres1; virus; promoter; cell
Prior art date: 1993-07-30

Application number

AT0150494A

Other languages

German (de)

English (en)

Other versions

ATA150494A (de

Inventor

Friedrich Dorner

Michael Dr Pfleiderer

Falko-Guenter Dr Falkner

Original Assignee

Immuno Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-07-30

Filing date

1994-07-29

Publication date

2002-12-27

1994-07-29 Application filed by Immuno Ag filed Critical Immuno Ag

2002-04-15 Publication of ATA150494A publication Critical patent/ATA150494A/de

2002-12-27 Application granted granted Critical

2002-12-27 Publication of AT409863B publication Critical patent/AT409863B/de

Links

108091007433 antigens Proteins 0.000 title claims description 190
239000000427 antigen Substances 0.000 title claims description 187
102000036639 antigens Human genes 0.000 title claims description 186
241000700721 Hepatitis B virus Species 0.000 title claims description 129
230000014509 gene expression Effects 0.000 title description 65
108090000765 processed proteins & peptides Proteins 0.000 title description 19
102000004196 processed proteins & peptides Human genes 0.000 title description 16
229920001184 polypeptide Polymers 0.000 title description 13
108090000623 proteins and genes Proteins 0.000 claims description 168
210000004027 cell Anatomy 0.000 claims description 148
241000700618 Vaccinia virus Species 0.000 claims description 100
102000004169 proteins and genes Human genes 0.000 claims description 93
241000700605 Viruses Species 0.000 claims description 75
239000012634 fragment Substances 0.000 claims description 52
229960005486 vaccine Drugs 0.000 claims description 47
238000000034 method Methods 0.000 claims description 42
108091033319 polynucleotide Proteins 0.000 claims description 37
102000040430 polynucleotide Human genes 0.000 claims description 37
239000002157 polynucleotide Substances 0.000 claims description 37
206010046865 Vaccinia virus infection Diseases 0.000 claims description 34
208000007089 vaccinia Diseases 0.000 claims description 34
208000015181 infectious disease Diseases 0.000 claims description 32
230000000091 immunopotentiator Effects 0.000 claims description 27
241000701832 Enterobacteria phage T3 Species 0.000 claims description 20
210000005229 liver cell Anatomy 0.000 claims description 20
239000003153 chemical reaction reagent Substances 0.000 claims description 19
210000001744 T-lymphocyte Anatomy 0.000 claims description 15
210000003527 eukaryotic cell Anatomy 0.000 claims description 14
210000003719 b-lymphocyte Anatomy 0.000 claims description 13
108091026890 Coding region Proteins 0.000 claims description 12
230000015572 biosynthetic process Effects 0.000 claims description 11
101150106093 gpt gene Proteins 0.000 claims description 11
239000003550 marker Substances 0.000 claims description 11
101000686777 Escherichia phage T7 T7 RNA polymerase Proteins 0.000 claims description 10
238000012258 culturing Methods 0.000 claims description 10
210000003292 kidney cell Anatomy 0.000 claims description 9
230000009089 cytolysis Effects 0.000 claims description 8
238000002955 isolation Methods 0.000 claims description 7
238000003786 synthesis reaction Methods 0.000 claims description 7
241000588724 Escherichia coli Species 0.000 claims description 6
210000004962 mammalian cell Anatomy 0.000 claims description 6
241000124008 Mammalia Species 0.000 claims description 5
230000003053 immunization Effects 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 3
238000004140 cleaning Methods 0.000 claims 2
238000011084 recovery Methods 0.000 claims 2
235000018102 proteins Nutrition 0.000 description 83
239000013612 plasmid Substances 0.000 description 53
108020004414 DNA Proteins 0.000 description 40
239000002245 particle Substances 0.000 description 30
239000013598 vector Substances 0.000 description 26
108700012359 toxins Proteins 0.000 description 22
239000006166 lysate Substances 0.000 description 19
239000003053 toxin Substances 0.000 description 19
231100000765 toxin Toxicity 0.000 description 19
101150082969 SELP gene Proteins 0.000 description 18
101150036293 Selenop gene Proteins 0.000 description 18
238000001262 western blot Methods 0.000 description 17
208000002672 hepatitis B Diseases 0.000 description 16
230000005847 immunogenicity Effects 0.000 description 16
108010090054 Membrane Glycoproteins Proteins 0.000 description 15
102000012750 Membrane Glycoproteins Human genes 0.000 description 14
238000010790 dilution Methods 0.000 description 14
239000012895 dilution Substances 0.000 description 14
238000003752 polymerase chain reaction Methods 0.000 description 14
108700026244 Open Reading Frames Proteins 0.000 description 13
239000000523 sample Substances 0.000 description 13
238000004519 manufacturing process Methods 0.000 description 12
239000002609 medium Substances 0.000 description 12
230000028993 immune response Effects 0.000 description 11
240000004808 Saccharomyces cerevisiae Species 0.000 description 10
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 10
150000001413 amino acids Chemical class 0.000 description 10
239000000203 mixture Substances 0.000 description 10
108091034117 Oligonucleotide Proteins 0.000 description 9
230000000890 antigenic effect Effects 0.000 description 9
238000013518 transcription Methods 0.000 description 9
230000035897 transcription Effects 0.000 description 9
101710137500 T7 RNA polymerase Proteins 0.000 description 8
235000001014 amino acid Nutrition 0.000 description 8
201000010099 disease Diseases 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
238000009396 hybridization Methods 0.000 description 8
230000002163 immunogen Effects 0.000 description 8
108020004999 messenger RNA Proteins 0.000 description 8
108010053187 Diphtheria Toxin Proteins 0.000 description 7
239000000020 Nitrocellulose Substances 0.000 description 7
238000010367 cloning Methods 0.000 description 7
239000013599 cloning vector Substances 0.000 description 7
238000001514 detection method Methods 0.000 description 7
230000002458 infectious effect Effects 0.000 description 7
229920001220 nitrocellulos Polymers 0.000 description 7
239000002773 nucleotide Substances 0.000 description 7
125000003729 nucleotide group Chemical group 0.000 description 7
102000016607 Diphtheria Toxin Human genes 0.000 description 6
238000002965 ELISA Methods 0.000 description 6
241000282412 Homo Species 0.000 description 6
108091028043 Nucleic acid sequence Proteins 0.000 description 6
239000000969 carrier Substances 0.000 description 6
238000010276 construction Methods 0.000 description 6
230000000694 effects Effects 0.000 description 6
230000004927 fusion Effects 0.000 description 6
239000000463 material Substances 0.000 description 6
231100000350 mutagenesis Toxicity 0.000 description 6
238000002703 mutagenesis Methods 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
230000028327 secretion Effects 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
239000000126 substance Substances 0.000 description 6
102000002260 Alkaline Phosphatase Human genes 0.000 description 5
108020004774 Alkaline Phosphatase Proteins 0.000 description 5
108091081024 Start codon Proteins 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
238000004113 cell culture Methods 0.000 description 5
239000000499 gel Substances 0.000 description 5
230000010354 integration Effects 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
229920002401 polyacrylamide Polymers 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
239000011550 stock solution Substances 0.000 description 5
238000002255 vaccination Methods 0.000 description 5
230000003612 virological effect Effects 0.000 description 5
102000053602 DNA Human genes 0.000 description 4
101150106741 Elp4 gene Proteins 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
108020004682 Single-Stranded DNA Proteins 0.000 description 4
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
210000000170 cell membrane Anatomy 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
230000002637 immunotoxin Effects 0.000 description 4
229940051026 immunotoxin Drugs 0.000 description 4
239000002596 immunotoxin Substances 0.000 description 4
231100000608 immunotoxin Toxicity 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
231100000654 protein toxin Toxicity 0.000 description 4
238000000746 purification Methods 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
230000010076 replication Effects 0.000 description 4
230000004044 response Effects 0.000 description 4
239000007787 solid Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
230000014616 translation Effects 0.000 description 4
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
108010049048 Cholera Toxin Proteins 0.000 description 3
102000009016 Cholera Toxin Human genes 0.000 description 3
241000710188 Encephalomyocarditis virus Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
102000018697 Membrane Proteins Human genes 0.000 description 3
108010052285 Membrane Proteins Proteins 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
108010081690 Pertussis Toxin Proteins 0.000 description 3
239000004793 Polystyrene Substances 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
239000012722 SDS sample buffer Substances 0.000 description 3
PBUXMVYWOSKHMF-WDSKDSINSA-N Ser-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CO PBUXMVYWOSKHMF-WDSKDSINSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
QJKMCQRFHJRIPU-XDTLVQLUSA-N Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 QJKMCQRFHJRIPU-XDTLVQLUSA-N 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000027455 binding Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
238000011109 contamination Methods 0.000 description 3
239000003814 drug Substances 0.000 description 3
210000002472 endoplasmic reticulum Anatomy 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 3
229940124736 hepatitis-B vaccine Drugs 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
231100000219 mutagenic Toxicity 0.000 description 3
230000003505 mutagenic effect Effects 0.000 description 3
150000007523 nucleic acids Chemical group 0.000 description 3
229920002223 polystyrene Polymers 0.000 description 3
230000002265 prevention Effects 0.000 description 3
238000010188 recombinant method Methods 0.000 description 3
230000006798 recombination Effects 0.000 description 3
238000005215 recombination Methods 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
108010071207 serylmethionine Proteins 0.000 description 3
239000000829 suppository Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000002103 transcriptional effect Effects 0.000 description 3
238000012546 transfer Methods 0.000 description 3
238000013519 translation Methods 0.000 description 3
238000011282 treatment Methods 0.000 description 3
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
108010066676 Abrin Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
208000003322 Coinfection Diseases 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
101710146739 Enterotoxin Proteins 0.000 description 2
101710082714 Exotoxin A Proteins 0.000 description 2
241000700662 Fowlpox virus Species 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
102000008100 Human Serum Albumin Human genes 0.000 description 2
108091006905 Human Serum Albumin Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
101710084021 Large envelope protein Proteins 0.000 description 2
241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
108010039491 Ricin Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
241000191940 Staphylococcus Species 0.000 description 2
108010003533 Viral Envelope Proteins Proteins 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
102000023732 binding proteins Human genes 0.000 description 2
108091008324 binding proteins Proteins 0.000 description 2
239000000872 buffer Substances 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000012412 chemical coupling Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000011969 continuous reassessment method Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
101150044687 crm gene Proteins 0.000 description 2
238000005520 cutting process Methods 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000010217 densitometric analysis Methods 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
230000029087 digestion Effects 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
239000000147 enterotoxin Substances 0.000 description 2
231100000655 enterotoxin Toxicity 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
230000012010 growth Effects 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
230000036039 immunity Effects 0.000 description 2
238000012744 immunostaining Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
201000008968 osteosarcoma Diseases 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
239000004800 polyvinyl chloride Substances 0.000 description 2
229920000915 polyvinyl chloride Polymers 0.000 description 2
230000004481 post-translational protein modification Effects 0.000 description 2
230000001323 posttranslational effect Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
238000010186 staining Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
230000005945 translocation Effects 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
210000003501 vero cell Anatomy 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
ZXXTYLFVENEGIP-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;3,7-dihydropurine-2,6-dione Chemical compound O=C1NC(N)=NC2=C1NC=N2.O=C1NC(=O)NC2=C1NC=N2 ZXXTYLFVENEGIP-UHFFFAOYSA-N 0.000 description 1
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
241000700663 Avipoxvirus Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
241000120506 Bluetongue virus Species 0.000 description 1
101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
201000006082 Chickenpox Diseases 0.000 description 1
241001227713 Chiron Species 0.000 description 1
102100031673 Corneodesmosin Human genes 0.000 description 1
101710139375 Corneodesmosin Proteins 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
241000186227 Corynebacterium diphtheriae Species 0.000 description 1
241000702141 Corynephage beta Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
101800000585 Diphtheria toxin fragment A Proteins 0.000 description 1
108700043113 E coli Gpt Proteins 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
102000002464 Galactosidases Human genes 0.000 description 1
108010093031 Galactosidases Proteins 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
101710121697 Heat-stable enterotoxin Proteins 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
102100034349 Integrase Human genes 0.000 description 1
108091029795 Intergenic region Proteins 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
101710175243 Major antigen Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
235000021360 Myristic acid Nutrition 0.000 description 1
101150008132 NDE1 gene Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
241000235648 Pichia Species 0.000 description 1
208000007452 Plasmacytoma Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
241000288906 Primates Species 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
101150087119 SAG gene Proteins 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
101710147732 Small envelope protein Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
101710137302 Surface antigen S Proteins 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
206010046980 Varicella Diseases 0.000 description 1
241000607626 Vibrio cholerae Species 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
239000002253 acid Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229940037003 alum Drugs 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
YTCZZXIRLARSET-VJRSQJMHSA-M beraprost sodium Chemical compound [Na+].O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC([O-])=O YTCZZXIRLARSET-VJRSQJMHSA-M 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
101150055766 cat gene Proteins 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000010382 chemical cross-linking Methods 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
210000001840 diploid cell Anatomy 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001400 expression cloning Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000004744 fabric Substances 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
102000054766 genetic haplotypes Human genes 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
108010004164 hepatitis B surface antigen presurface protein 1 Proteins 0.000 description 1
108700017737 hepatitis B virus L Proteins 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
230000002434 immunopotentiative effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000004020 intracellular membrane Anatomy 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000003446 ligand Substances 0.000 description 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000001320 lysogenic effect Effects 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000012528 membrane Substances 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
238000012510 peptide mapping method Methods 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
230000020978 protein processing Effects 0.000 description 1
230000012743 protein tagging Effects 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
238000011896 sensitive detection Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
229940125575 vaccine candidate Drugs 0.000 description 1
229940021648 varicella vaccine Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229940118696 vibrio cholerae Drugs 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5761—Hepatitis B
- G01N33/5764—Hepatitis B surface antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/82—Hepatitis associated antigens and antibodies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Communicable Diseases (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

AT0150494A 1993-07-30 1994-07-29 Hoch effiziente expression eines polypeptids, das eine modifizierte pres1-region des grossen hepatitis b-virus-antigens enthält AT409863B (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US9935193A	1993-07-30	1993-07-30

Publications (2)

Publication Number	Publication Date
ATA150494A ATA150494A (de)	2002-04-15
AT409863B true AT409863B (de)	2002-12-27

Family

ID=22274582

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT0150494A AT409863B (de)	1993-07-30	1994-07-29	Hoch effiziente expression eines polypeptids, das eine modifizierte pres1-region des grossen hepatitis b-virus-antigens enthält

Country Status (4)

Country	Link
US (2)	US6077691A (fr)
EP (1)	EP0637631A3 (fr)
AT (1)	AT409863B (fr)
CA (1)	CA2129156A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0753581A1 (fr)	1995-07-10	1997-01-15	Immuno Ag	Virus recombinantes eucaryotes cytoplasmiques améliorés, un procédé pour leur préparation et leur utilisation comme vaccins
TWI691598B (zh) *	2015-10-08	2020-04-21	台灣生物製劑股份有限公司	以整體表現細胞作為抗原載體及其於製備疫苗或診斷試劑及篩選單株抗體之應用
JP2020108355A (ja) *	2019-01-07	2020-07-16	公益財団法人ヒューマンサイエンス振興財団	Ｂ型肝炎ウイルス株

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0414374A2 (fr) *	1989-07-25	1991-02-27	Smithkline Biologicals S.A.	Antigènes ainsi que les méthodes pour leur préparation
US5077213A (en) *	1988-11-10	1991-12-31	Shanghai Institute Of Biochemistry, Chinese Academy Of Sciences	Recombinant vaccinia virus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4847080A (en) *	1984-03-07	1989-07-11	New York Blood Center, Inc.	Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers
EP1088830A3 (fr) *	1987-06-22	2004-04-07	Medeva Holdings B.V.	Particules de l'antigène de surface de l'hépatitie B

1994
- 1994-07-29 EP EP94111872A patent/EP0637631A3/fr not_active Withdrawn
- 1994-07-29 CA CA002129156A patent/CA2129156A1/fr not_active Abandoned
- 1994-07-29 AT AT0150494A patent/AT409863B/de not_active IP Right Cessation
1997
- 1997-02-06 US US08/796,415 patent/US6077691A/en not_active Expired - Fee Related
- 1997-02-07 US US08/797,629 patent/US6004561A/en not_active Expired - Fee Related

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5077213A (en) *	1988-11-10	1991-12-31	Shanghai Institute Of Biochemistry, Chinese Academy Of Sciences	Recombinant vaccinia virus
EP0414374A2 (fr) *	1989-07-25	1991-02-27	Smithkline Biologicals S.A.	Antigènes ainsi que les méthodes pour leur préparation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHENG ET AL., JOURNAL OF VIROLOGY (1986), V. 60, NO. 2, S. 337-344 *
ELROY-STEIN ET AL., PROC. NATL. ACAD. SCI. (1989), V. 86, S. 6126-6130 *
FÜRST ET AL., MOL. AND CELL. BIOLOGY (1987), V. 7, NO. 7, S. 2538-2544 *
NEMECKOVA ET AL., ARCH. VIROL. (1991), V. 121, S. 29-41 *

Also Published As

Publication number	Publication date
US6077691A (en)	2000-06-20
EP0637631A3 (fr)	1996-08-21
ATA150494A (de)	2002-04-15
EP0637631A2 (fr)	1995-02-08
CA2129156A1 (fr)	1995-01-31
US6004561A (en)	1999-12-21

Legal Events

Date	Code	Title	Description
1997-10-15	UEP	Publication of translation of european patent specification
2005-12-15	ELJ	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE3788902T3 (de)	2004-11-25	Hepatitis-Delta-Diagnostika und Impfstoffe, ihre Herstellung und Verwendung.
DE3650536T2 (de)	1997-02-27	Mittels rekombinanter DNS-Techniken gebildetes Hepatitis-B-Oberflächenantigen, Impfstoffe, Diagnostika, Zellinien und Verfahren zu deren Herstellung
DE69031556T2 (de)	1998-05-14	Antigene sowie Verfahren zu deren Herstellung
DE69111801T2 (de)	1995-12-14	Vakzin gegen hepatitis b.
DE69433285T2 (de)	2004-06-24	Hepatitis-b-virusmutanten, und verbindungen und verfahren für ihre bestimmung
DE3587991T2 (de)	1995-07-20	Rekombinanter herpes simplex gb-gd impfstoff.
DE3382659T2 (de)	1993-09-02	Verfahren zur herstellung von poxvirus-rekombinanten zur expression fremder gene.
DE68929478T2 (de)	2004-04-29	Rekombinante CMV-Neutralisierungsproteine
DD285994A5 (de)	1991-01-10	Verfahren zur herstellung eines hbv-impfstoffes
DE69130071T3 (de)	2008-02-21	Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
DE3072205T2 (de)	1993-08-05	Dns-transfer-vektor, damit transformierter wirt, impfstoff und ihre herstellung.
DE3789399T2 (de)	1994-10-06	Herstellung von Vakkzinen gegen Hepatitis B-Virus.
DE3856496T2 (de)	2002-06-27	Hepatitis-B-Oberflächenantigen enthaltendes Peptid
DE69131200T2 (de)	1999-12-09	Herpes simplex virus vp16 impfstoffe
JPH01503675A (ja)	1989-12-14	中空ウイルスキヤプシドのワクチン
JPH02500409A (ja)	1990-02-15	弱毒化ヘルペスウイルス、アミノ酸配列コード化外来ｄｎａ含有ヘルペスウイルス並びに同上含有ワクチン
IE903370A1 (en)	1991-04-10	Chimaeric hepadnavirus core antigen proteins
DE69332045T2 (de)	2002-10-17	Hepatistherapeutikum
HU196625B (en)	1988-12-28	Process for producing hepatitis b virus vaccine
DE69535561T2 (de)	2008-06-05	NUKLEOTID- UND AMINOSÄURESEQUENZEN gB, gC UND gD DES HERPESVIRUS DES HUNDES UND IHRE VERWENDUNGEN
DE69524415T2 (de)	2002-08-01	UNGESPLEISSTE VARIANTEN DES gp350/220
AU1278097A (en)	1997-06-19	Recombinant poxvirus-feline infectious peritonitis virus, compositions thereof and methods for making and using them
DE10339927A1 (de)	2005-03-24	Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen
DE3685837T2 (de)	1992-12-17	Hepatitis-a-virus-impfstoff.
AT409863B (de)	2002-12-27	Hoch effiziente expression eines polypeptids, das eine modifizierte pres1-region des grossen hepatitis b-virus-antigens enthält